بايونتيك وبريستول مايرز سكويب تعلنان عن بيانات عالمية مشجعة للمرحلة الثانية لعقار Pumitamig في علاج سرطان الرئة غير الصغير المتقدم بعد تفاقم المرض رغم العلاج المناعي والكيميائي

BioNTech and Bristol Myers Squibb jointly announced encouraging global Phase 2 clinical trial results for Pumitamig in patients with advanced non-small cell lung cancer. The trial evaluated Pumitamig combined with docetaxel in individuals who experienced disease progression following prior immunotherapy and chemotherapy regimens. Results demonstrated a confirmed objective response rate of 36.7% across both squamous and non-squamous patient cohorts regardless of PD-L1 expression levels. Furthermore, the combination therapy exhibited an encouraging early median progression-free survival profile in this heavily pre-treated population. These clinical findings suggest a potential new therapeutic avenue for patients with limited remaining treatment options. Both pharmaceutical partners plan to advance the clinical development program toward late-stage pivotal trials.